ImmunoGen, Inc.
IMGN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 55.7% | -47.2% | 60.8% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 99.8% | 100% | 13.4% | -39.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -198.3% | -177.8% | -14.9% | -79.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -204.9% | -199.4% | -50.4% | -148.4% |
| EPS Diluted | -0.879 | -1.081 | -0.38 | -0.82 |
| % Growth | 18.7% | -184.6% | 53.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |